SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
RKDA reported Third Quarter 2026 results. The price and volatility reaction is pending.
RKDAearnings

Earnings reactions, page 3

Arcadia Biosciences, Inc. (RKDA) Q3 FY2026 earnings

November 13, 2026 · SharpeIQ Research Desk

Reported results

  • Total revenues were $1,619,000 for the third quarter of 2026 compared to $1,302,000 for the third quarter of 2025.
  • Total operating expenses were $2,458,000 for the third quarter of 2026 compared to $2,454,000 for the third quarter of 2025.
  • Loss from continuing operations was $839,000 for the third quarter of 2026 compared to $1,152,000 for the third quarter of 2025.
  • Net income attributable to common stockholders was $1,755,000 for the third quarter of 2026 compared to $856,000 for the third quarter of 2025.
  • Selling, general, and administrative (SG&A) expenses increased by $128,000 during the third quarter of 2026 compared to the same period in 2025.

Guidance

  • Zola Original, Original with Pulp, and Espresso varieties will be available in a 10.5-ounce slim can in the first half of next year.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →